{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Makerfield&writtenParliamentaryQuestionType=NamedDay", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberConstituency=Makerfield&writtenParliamentaryQuestionType=NamedDay", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Makerfield&_metadata=all&writtenParliamentaryQuestionType=NamedDay", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&tablingMemberConstituency=Makerfield&writtenParliamentaryQuestionType=NamedDay", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Makerfield&writtenParliamentaryQuestionType=NamedDay", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Makerfield&writtenParliamentaryQuestionType=NamedDay", "items" : [{"_about" : "http://data.parliament.uk/resources/1456349", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1456349/answer", "answerText" : {"_value" : "<p>The NHS England and NHS Improvement Accelerated Access Collaborative (AAC) on Improving Access to Biologic Therapy estimates that approximately 200,000 or 5% of patients with asthma have severe asthma. Of these patients, the AAC estimates that between 50,000 to 100,000 may be eligible for biologic therapy, with approximately 11,000 patients receiving this treatment. The AAC aims to improve the identification of these patients in primary and secondary care settings, to allow referrals to specialist severe asthma centres to determine their suitability for biologic treatment.<\/p><p>No specific estimate of the number of patients awaiting an appointment at a severe asthma centre has been made as this information is not collected in the format requested. No specific assessment has been made of the effectiveness of home administration of biologics for severe asthma. The National Institute for Health and Care Excellence\u2019s COVID-19 rapid guideline on severe asthma promoted the use of home administration for biologic treatments to maintain access and reduce risks to patients of COVID-19 exposure. While we are ensuring that patients who are eligible for this treatment are able to access it, there are no plans to extend the eligibility criteria.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4680", "label" : {"_value" : "Biography information for Gillian Keegan"}
        }
        , "answeringMemberConstituency" : {"_value" : "Chichester"}
        , "answeringMemberPrinted" : {"_value" : "Gillian Keegan"}
        , "dateOfAnswer" : {"_value" : "2022-04-19", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "151059"}
        , {"_value" : "151060"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-19T11:47:25.483Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-03-31", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients who are eligible for biologic treatment for severe asthma who are not currently accessing it.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "151058"}
    , {"_about" : "http://data.parliament.uk/resources/1456350", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1456350/answer", "answerText" : {"_value" : "<p>The NHS England and NHS Improvement Accelerated Access Collaborative (AAC) on Improving Access to Biologic Therapy estimates that approximately 200,000 or 5% of patients with asthma have severe asthma. Of these patients, the AAC estimates that between 50,000 to 100,000 may be eligible for biologic therapy, with approximately 11,000 patients receiving this treatment. The AAC aims to improve the identification of these patients in primary and secondary care settings, to allow referrals to specialist severe asthma centres to determine their suitability for biologic treatment.<\/p><p>No specific estimate of the number of patients awaiting an appointment at a severe asthma centre has been made as this information is not collected in the format requested. No specific assessment has been made of the effectiveness of home administration of biologics for severe asthma. The National Institute for Health and Care Excellence\u2019s COVID-19 rapid guideline on severe asthma promoted the use of home administration for biologic treatments to maintain access and reduce risks to patients of COVID-19 exposure. While we are ensuring that patients who are eligible for this treatment are able to access it, there are no plans to extend the eligibility criteria.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4680", "label" : {"_value" : "Biography information for Gillian Keegan"}
        }
        , "answeringMemberConstituency" : {"_value" : "Chichester"}
        , "answeringMemberPrinted" : {"_value" : "Gillian Keegan"}
        , "dateOfAnswer" : {"_value" : "2022-04-19", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "151058"}
        , {"_value" : "151060"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-19T11:47:25.547Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-03-31", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients awaiting an appointment at a severe asthma centre.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "151059"}
    , {"_about" : "http://data.parliament.uk/resources/1456351", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1456351/answer", "answerText" : {"_value" : "<p>The NHS England and NHS Improvement Accelerated Access Collaborative (AAC) on Improving Access to Biologic Therapy estimates that approximately 200,000 or 5% of patients with asthma have severe asthma. Of these patients, the AAC estimates that between 50,000 to 100,000 may be eligible for biologic therapy, with approximately 11,000 patients receiving this treatment. The AAC aims to improve the identification of these patients in primary and secondary care settings, to allow referrals to specialist severe asthma centres to determine their suitability for biologic treatment.<\/p><p>No specific estimate of the number of patients awaiting an appointment at a severe asthma centre has been made as this information is not collected in the format requested. No specific assessment has been made of the effectiveness of home administration of biologics for severe asthma. The National Institute for Health and Care Excellence\u2019s COVID-19 rapid guideline on severe asthma promoted the use of home administration for biologic treatments to maintain access and reduce risks to patients of COVID-19 exposure. While we are ensuring that patients who are eligible for this treatment are able to access it, there are no plans to extend the eligibility criteria.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4680", "label" : {"_value" : "Biography information for Gillian Keegan"}
        }
        , "answeringMemberConstituency" : {"_value" : "Chichester"}
        , "answeringMemberPrinted" : {"_value" : "Gillian Keegan"}
        , "dateOfAnswer" : {"_value" : "2022-04-19", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "151058"}
        , {"_value" : "151059"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-19T11:47:25.6Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-03-31", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of home administration of biologics for severe asthma; and whether he has plans to extend that treatment.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "151060"}
    , {"_about" : "http://data.parliament.uk/resources/1419854", "AnsweringBody" : [{"_value" : "Department for Digital, Culture, Media and Sport"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1419854/answer", "answerText" : {"_value" : "<p>Security requirements to be set out using the powers in the Product Security and Telecommunications Infrastructure Bill will have to be complied with relation to all relevant consumer connectable products sold to customers in the UK, including those sold on online marketplaces.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4647", "label" : {"_value" : "Biography information for Julia Lopez"}
        }
        , "answeringMemberConstituency" : {"_value" : "Hornchurch and Upminster"}
        , "answeringMemberPrinted" : {"_value" : "Julia Lopez"}
        , "dateOfAnswer" : {"_value" : "2022-02-09", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-02-09T14:02:47.163Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "10"}
      , "answeringDeptShortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "answeringDeptSortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "date" : {"_value" : "2022-02-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Smart Devices: Electronic Commerce"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Digital, Culture, Media and Sport, whether smart products sold on online marketplaces will be subject to the provisions of the Product Security and Telecommunications Infrastructure Bill.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "118527"}
    , {"_about" : "http://data.parliament.uk/resources/1419855", "AnsweringBody" : [{"_value" : "Department for Digital, Culture, Media and Sport"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1419855/answer", "answerText" : {"_value" : "<p>The Product Security and Telecommunications Infrastructure Bill includes provisions that allow the Secretary of State to issue recall notices relating to relevant insecure consumer connected products, if deemed appropriate.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4647", "label" : {"_value" : "Biography information for Julia Lopez"}
        }
        , "answeringMemberConstituency" : {"_value" : "Hornchurch and Upminster"}
        , "answeringMemberPrinted" : {"_value" : "Julia Lopez"}
        , "dateOfAnswer" : {"_value" : "2022-02-09", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-02-09T14:04:25.603Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "10"}
      , "answeringDeptShortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "answeringDeptSortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "date" : {"_value" : "2022-02-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Smart Devices"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Digital, Culture, Media and Sport, whether she plans to include provisions for when a smart product is recalled within the Product Security and Telecommunications Infrastructure Bill.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "118528"}
    , {"_about" : "http://data.parliament.uk/resources/1387201", "AnsweringBody" : [{"_value" : "Ministry of Justice"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1387201/answer", "answerText" : {"_value" : "<p>The Ministry of Justice strongly supports the creation of the independent oversight body for enforcement agents and firms that has been proposed by the Centre for Social Justice (CSJ). Officials have met regularly with the CSJ and the working group that is establishing the body to support its development. We will undertake a review of the body within two years of its operation to see if any legislative changes are necessary to place it on a statutory footing.<\/p><p>The publication of the response to our call for evidence about the enforcement agent reforms, which closed in February 2019, has been delayed as a result of the department\u2019s response to the pandemic. That allowed us to refocus our priorities, which resulted, for example, in MoJ and DLUHC introducing an extended ban on enforcing evictions to prevent people being made homeless during Covid, so protecting public health and easing the burden on the NHS and local authorities.<\/p><p>We remain committed to raising standards in this sector and will publish the response as soon as possible.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4519", "label" : {"_value" : "Biography information for James Cartlidge"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Suffolk"}
        , "answeringMemberPrinted" : {"_value" : "James Cartlidge"}
        , "dateOfAnswer" : {"_value" : "2021-12-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-12-20T16:23:33.21Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "54"}
      , "answeringDeptShortName" : {"_value" : "Justice"}
      , "answeringDeptSortName" : {"_value" : "Justice"}
      , "date" : {"_value" : "2021-12-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Enforcement"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Justice, what steps the Government has taken to support the establishment of the Enforcement Conduct Authority proposed by Centre for Social Justice; and when his Department plans to publish the results of its 2018 call for evidence on enforcement agent reforms.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "91951"}
    , {"_about" : "http://data.parliament.uk/resources/1353444", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1353444/answer", "answerText" : {"_value" : "<p>No estimate has been made and information on the number of severe asthma patients are receiving biologic therapies is not available in the format requested.<\/p><p> <\/p><p> <\/p><p>Clinicians are responsible for making prescribing decisions for their patients, taking into account the National Institute for Health and Care Excellence\u2019s technology appraisals and guidance on management of asthma and the local commissioning decisions. Prescribing of biologics for severe asthma is co-ordinated through severe asthma centre multi-disciplinary teams to ensure current treatments are optimised and all appropriate treatments are considered with use of biologics as part of the treatment review for each patient.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2021-09-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "44319"}
        , {"_value" : "44320"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-09-16T15:01:18.38Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-09-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the size of the eligible population among severe asthma suffers for biologic treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "44318"}
    , {"_about" : "http://data.parliament.uk/resources/1353445", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1353445/answer", "answerText" : {"_value" : "<p>No estimate has been made and information on the number of severe asthma patients are receiving biologic therapies is not available in the format requested.<\/p><p> <\/p><p> <\/p><p>Clinicians are responsible for making prescribing decisions for their patients, taking into account the National Institute for Health and Care Excellence\u2019s technology appraisals and guidance on management of asthma and the local commissioning decisions. Prescribing of biologics for severe asthma is co-ordinated through severe asthma centre multi-disciplinary teams to ensure current treatments are optimised and all appropriate treatments are considered with use of biologics as part of the treatment review for each patient.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2021-09-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "44318"}
        , {"_value" : "44320"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-09-16T15:01:18.417Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-09-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many severe asthma patients are receiving biologic therapies through (a) the severe asthma networks and (b) other services.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "44319"}
    , {"_about" : "http://data.parliament.uk/resources/1353446", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1353446/answer", "answerText" : {"_value" : "<p>No estimate has been made and information on the number of severe asthma patients are receiving biologic therapies is not available in the format requested.<\/p><p> <\/p><p> <\/p><p>Clinicians are responsible for making prescribing decisions for their patients, taking into account the National Institute for Health and Care Excellence\u2019s technology appraisals and guidance on management of asthma and the local commissioning decisions. Prescribing of biologics for severe asthma is co-ordinated through severe asthma centre multi-disciplinary teams to ensure current treatments are optimised and all appropriate treatments are considered with use of biologics as part of the treatment review for each patient.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2021-09-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "44318"}
        , {"_value" : "44319"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-09-16T15:01:18.463Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-09-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the geographical variation in the prescribing of biologics for severe asthma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "44320"}
    , {"_about" : "http://data.parliament.uk/resources/1353447", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1353447/answer", "answerText" : {"_value" : "<p>Specialist respiratory services for severe asthma, along with urgent and emergency treatment for other serious complaints, have continued throughout the COVID-19 outbreak. In most cases people with severe asthma have been able to receive their medication at home instead of having to attend hospital.<\/p><p>The National Institute for Health and Care Excellence COVID-19 rapid guideline on severe asthma promoted the use of home delivery for biologic treatments to maintain access and reduce the risks to patients of COVID-19 exposure. The NHS England severe asthma \u2018Accelerated Access Collaborative\u2019 will continue to focus on the area of home administration.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2021-09-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-09-10T13:13:49.163Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-09-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what help is available for asthma sufferers to enable them to continue to self-administer their medication due to the pressures on the NHS during the covid-19 outbreak.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4034", "label" : {"_value" : "Biography information for Yvonne Fovargue"}
      }
      , "tablingMemberConstituency" : {"_value" : "Makerfield"}
      , "tablingMemberPrinted" : [{"_value" : "Yvonne Fovargue"}
      ], "uin" : "44321"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&tablingMemberConstituency=Makerfield&writtenParliamentaryQuestionType=NamedDay", "page" : 0, "startIndex" : 1, "totalResults" : 44, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}